Jorge Hernandez, MD
Cardiovascular Disease · Beaumont, TXNPI 1356338347
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (54.4%), other and education — rather than concentrated in one kind of arrangement. 34 manufacturers reported payments, led by Angiodynamics, Inc. at 39.6% of the total. Reporting peaked in 2022 at $6,504 and has fallen 68.6% since, to $2,039 in 2025.
Across 414 payments — averaging $41.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Angiodynamics, Inc.$7K
- Abbott$2K
- Boston Scientific$2K
- Shockwave Medical, Inc$1K
- Edwards Lifesciences$1K
- Merck$621
- plus $3K from 28 others
Across 56 payments — averaging $5307.81 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Currax Pharmaceuticals LLC$184K
- AstraZeneca$58K
- Alnylam Pharmaceuticals Inc.$23K
- Boehringer Ingelheim International GmbH$21K
- Boehringer Ingelheim Pharma GmbH & Co.kg$10K
What the payments were for
- Travel & lodging$1,0426%
- Food & beverage$9,43854%
- Education$1,3007%
- Other$5,58332%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Angiodynamics, Inc. | 2 | $6,883 |
| Abbott | 45 | $2,322 |
| Boston Scientific | 62 | $2,033 |
| Shockwave Medical, Inc | 82 | $1,269 |
| Edwards Lifesciences | 59 | $1,130 |
| Merck | 32 | $621 |
| Siemens Medical Solutions USA, Inc. | 5 | $618 |
| Actelion Pharmaceuticals US, Inc. | 27 | $525 |
| E.r. Squibb & Sons, L.L.C. | 15 | $210 |
| AstraZeneca | 6 | $207 |
| Inspire Medical Systems, Inc. | 7 | $201 |
| Esperion Therapeutics, Inc. | 8 | $190 |
| Novartis | 10 | $165 |
| Johnson & Johnson | 10 | $131 |
| Pfizer | 7 | $103 |
| Amgen | 5 | $92 |
| Lexicon Pharmaceuticals, Inc. | 2 | $83 |
| Heartflow, Inc. | 1 | $76 |
| Cardiovascular Systems Inc. | 7 | $73 |
| Biotronik Inc. | 2 | $44 |
| Sanofi-aventis U.S. LLC | 3 | $43 |
| Boehringer Ingelheim | 2 | $42 |
| Catheter Precision, Inc. FKA Ra Medical Systems, Inc. | 2 | $36 |
| Atricure, Inc. | 1 | $35 |
| Cardiva Medical, Inc. | 1 | $35 |
| Akcea Therapeutics, Inc. | 1 | $31 |
| Amarin Pharma, Inc. | 2 | $30 |
| Innovation Technologies Inc | 1 | $28 |
| Bayer | 2 | $28 |
| Medtronic | 1 | $18 |
| Tactile Systems Technology Inc | 1 | $17 |
| Arbor Pharmaceuticals, Inc. | 1 | $15 |
| Irhythm Technologies, Inc. | 1 | $14 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Auryon Laser System 100-120 Vac$6,883
- NAEOTOM Alpha$577
- AVEIR$530
- VERQUVO$200
- Mitra Clip system$186
- FARXIGA$124
- Durata Defibrillation ICD Lead$111
- LATITUDE Communicator Power Supply$109
- SAPIEN 3 Ultra RESILIA$106
- NEXLIZET$103
- NEXLETOL$103
How this compares
$17,363 in reported general payments places this provider in the 85th percentile of 1,515 cardiovascular disease providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 677 | $656,718 |
| OpsumitMacitentan | 46 | $556,548 |
| EntrestoSacubitril/Valsartan | 223 | $212,007 |
| XareltoRivaroxaban | 183 | $158,059 |
| Repatha SureclickEvolocumab | 86 | $55,150 |
| FarxigaDapagliflozin Propanediol | 72 | $40,519 |
| VerquvoVericiguat | 20 | $19,945 |
| MultaqDronedarone Hcl | 18 | $16,142 |
| Ranolazine ErRanolazine | 194 | $16,022 |
| Metoprolol Succinate | 802 | $15,148 |
| BrilintaTicagrelor | 19 | $13,198 |
| InpefaSotagliflozin | 13 | $8,989 |
| Praluent PenAlirocumab | 18 | $8,967 |
| Prasugrel Hcl | 102 | $8,101 |
| ClopidogrelClopidogrel Bisulfate | 818 | $7,311 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $103 | $656,718677 claims |
| Actelion Pharmaceuticals US, Inc.Opsumit | $525 | $556,54846 claims |
| NovartisEntresto | $165 | $212,007223 claims |
| Johnson & JohnsonXarelto | $131 | $158,059183 claims |
| AstraZenecaFarxiga, Brilinta | $207 | $53,71791 claims |
| MerckVerquvo | $621 | $19,94520 claims |
| Sanofi-aventis U.S. LLCMultaq | $43 | $16,14218 claims |
| Lexicon Pharmaceuticals, Inc.Inpefa | $83 | $8,98913 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,515 cardiovascular disease providers in Texas.
Other cardiovascular disease in Beaumont
- Ramin Farzaneh-FarDallas$17.1M
- John OsborneGrapevine$1.3M
- Darren McGuireDallas$1.2M
- Peter McCulloughDallas$664K
- Ann NavarDallas$616K
- Biykem BozkurtHouston$606K
- Milton PackerDallas$530K
- Amarinder BindraDallas$512K
- Robert SalazarKingwood$478K
- Reynolds DelgadoHouston$471K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.